Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed.
Buy Sanofi India: target of Rs 9600: Sharekhan
Sharekhan is bullish on Sanofi India has recommended buy rating on the stock with a target price of Rs 9600 in its research report dated March 17, 2021. Sanofi India Call with Analysts and Investors
Conference Call with Sanofi India Management and Analysts on Q3FY21 Performance and Outlook. Listen to the full transcript. Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
We refer to our letter dated 24th February 2021 intimating you the details of the investor webinar which was scheduled today. Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the presentation made by the Company at the investor webinar is enclosed for your reference Sanofi India Ltd - 500674 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (Listing Regulations)
The audited financial results of the Company for the quarter and year ended 31st December 2020 were approved by the Board of Directors of the Company at its meeting held on 23rd February 2021 and published on 25th February 2021. Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed the disclosures of related party transactions for the half year ended 31st December 2020 in the format specified in the applicable accounting standards. Kindly take the above information on record. Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed copies of the newspaper publication related to notice of the Annual General Meeting which will be held through video conferencing facility on 27th April 2021, published today, in newspapers, Business Standard and Sakal.
Sanofi to start human trials of its second COVID vaccine candidate
Sanofi and US company Translate Bio are developing the vaccine based on messenger RNA technology. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has issued duplicate share certificates in lieu of the original share certificates reported lost/misplaced, details of which are enclosed. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed. Sanofi India Ltd - 500674 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has received communication from its Registrar and Share Transfer Agent on loss of share certificate(s), details of which are enclosed.